Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
47.49 USD +3.13% Intraday chart for Apellis Pharmaceuticals, Inc. -0.92% -20.66%
04-29 Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating MT
04-26 Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Mixed Premarket Friday
Apellis Pharmaceuticals Receives Negative EU Committee Opinion for Pegcetacoplan
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application
Apellis Pharmaceuticals Insider Sold Shares Worth $272,975, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $469,905, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $872,961, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $271,943, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLS Stock
  4. News Apellis Pharmaceuticals, Inc.
  5. Other languages